AG˹ٷ

STOCK TITAN

[Form 4] BigCommerce Holdings, Inc. Series 1 Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Form 4 filing overview: On 06/30/2025, MAIA Biotechnology, Inc. (ticker MAIA) granted director Cristian Luput a package of stock options under the company’s 2021 Equity Incentive Plan.

  • Options granted: 21,350 options to purchase common shares.
  • Exercise price: $1.80 per share.
  • Vesting schedule: 100% vested immediately on the grant date.
  • Expiration: 06/30/2035 (10-year term).
  • Post-transaction holdings: Luput now holds 21,350 derivative securities directly.

No non-derivative share transactions were reported, and the filing was made individually by the director. The grant represents routine equity compensation designed to align director incentives with shareholder value, but it modestly increases the company’s fully diluted share count.

Panoramica della segnalazione Form 4: Il 30/06/2025, MAIA Biotechnology, Inc. (simbolo MAIA) ha assegnato al direttore Cristian Luput un pacchetto di opzioni su azioni nell'ambito del Piano di Incentivazione Azionaria 2021 della società.

  • Opzioni assegnate: 21.350 opzioni per l'acquisto di azioni ordinarie.
  • Prezzo di esercizio: 1,80 $ per azione.
  • Piano di maturazione: 100% maturato immediatamente alla data di assegnazione.
  • Scadenza: 30/06/2035 (durata di 10 anni).
  • Detenzioni post-transazione: Luput detiene ora direttamente 21.350 strumenti derivati.

Non sono state segnalate transazioni su azioni non derivate e la comunicazione è stata effettuata individualmente dal direttore. L’assegnazione rappresenta una normale forma di compenso azionario finalizzata ad allineare gli interessi del direttore con il valore per gli azionisti, ma comporta un modesto aumento del numero totale di azioni diluite della società.

Resumen de la presentación del Formulario 4: El 30/06/2025, MAIA Biotechnology, Inc. (símbolo MAIA) otorgó al director Cristian Luput un paquete de opciones sobre acciones bajo el Plan de Incentivos de Capital 2021 de la empresa.

  • Opciones otorgadas: 21,350 opciones para comprar acciones ordinarias.
  • Precio de ejercicio: $1.80 por acción.
  • Calendario de adquisición: 100% adquirido inmediatamente en la fecha de otorgamiento.
  • Vencimiento: 30/06/2035 (plazo de 10 años).
  • Participaciones tras la transacción: Luput ahora posee directamente 21,350 valores derivados.

No se reportaron transacciones con acciones no derivadas y la presentación fue realizada individualmente por el director. La concesión representa una compensación accionaria rutinaria diseñada para alinear los incentivos del director con el valor para los accionistas, aunque aumenta modestamente el número total de acciones diluidas de la empresa.

Form 4 제출 개요: 2025� 6� 30�, MAIA Biotechnology, Inc. (티커 MAIA)� 이사 Cristian Luput에게 회사� 2021� 주식 인센티브 계획� 따라 주식 매수선택� 패키지� 부여했습니�.

  • 부여된 옵션: 보통� 21,350� 매수선택�.
  • 행사갶�: 주당 $1.80.
  • 권리 취득 일정: 부여일� 100% 즉시 취득.
  • 만료�: 2035� 6� 30� (10� 기간).
  • 거래 � 보유 현황: Luput� 현재 21,350개의 파생증권� 직접 보유 중입니다.

비파� 주식 거래� 보고되지 않았으며, 제출은 이사 개인� 직접 수행했습니다. 이번 부여는 이사� 인센티브� 주주 가치와 일치시키� 위한 일상적인 주식 보상으로, 회사� 완전 희석 주식 수를 다소 증가시키� 결과� 가져옵니다.

Résumé du dépôt du formulaire 4 : Le 30/06/2025, MAIA Biotechnology, Inc. (symbole MAIA) a accordé au directeur Cristian Luput un ensemble d’options d’achat d’actions dans le cadre du Plan d’Incitation en Actions 2021 de la société.

  • Options accordées : 21 350 options pour acheter des actions ordinaires.
  • Prix d’exercice : 1,80 $ par action.
  • Calendrier d’acquisition : 100 % acquis immédiatement à la date d’attribution.
  • Expiration : 30/06/2035 (durée de 10 ans).
  • Détentions après la transaction : Luput détient désormais directement 21 350 titres dérivés.

Aucune transaction sur actions non dérivées n’a été signalée, et le dépôt a été effectué individuellement par le directeur. Cette attribution représente une compensation en actions de routine visant à aligner les incitations du directeur avec la valeur pour les actionnaires, mais elle augmente modestement le nombre total d’actions diluées de la société.

Übersicht zur Form 4 Einreichung: Am 30.06.2025 gewährte MAIA Biotechnology, Inc. (Ticker MAIA) dem Direktor Cristian Luput ein Paket von Aktienoptionen im Rahmen des Aktienanreizplans 2021 des Unternehmens.

  • Gewährte Optionen: 21.350 Optionen zum Kauf von Stammaktien.
  • ܲüܲԲ𾱲: 1,80 $ pro Aktie.
  • Vesting-Zeitplan: 100 % sofort am Gewährungstag unverfallbar.
  • Ablaufdatum: 30.06.2035 (10 Jahre Laufzeit).
  • Bestände nach der Transaktion: Luput hält nun direkt 21.350 derivative Wertpapiere.

Es wurden keine Transaktionen mit nicht-derivativen Aktien gemeldet, und die Einreichung erfolgte individuell durch den Direktor. Die Gewährung stellt eine routinemäßige Aktienvergütung dar, die darauf abzielt, die Anreize des Direktors mit dem Aktionärswert in Einklang zu bringen, erhöht jedoch geringfügig die vollständig verwässerte Aktienanzahl des Unternehmens.

Positive
  • Equity alignment: Granting options encourages the director to focus on long-term share appreciation without immediate cash expenditure.
  • No cash impact: The award preserves corporate liquidity, critical for a development-stage biotech.
Negative
  • Immediate vesting: 100% vesting at grant provides limited retention incentive and accelerates expense recognition.
  • Incremental dilution: The issuance adds to fully diluted shares, albeit at a small scale.

Insights

TL;DR � Routine option grant; aligns incentives, minor dilution, overall neutral impact.

The single grant of 21,350 fully vested options to a non-employee director is standard practice for emerging biotech firms seeking to conserve cash while attracting board talent. Immediate vesting eliminates service-based retention value but allows instant alignment with shareholders. At an exercise price of $1.80, the options are only accretive if the share price exceeds this level, providing performance leverage without current cash cost. Given MAIA’s modest market capitalization, the incremental dilution is immaterial. I classify the filing as informational with no material balance-sheet impact.

TL;DR � Option grant modest in size; impact largely neutral for valuation.

The issuance adds roughly 0.1�0.2% to potential shares outstanding (exact percentage depends on MAIA’s total shares, which is not disclosed here). Because the options vest immediately, the related GAAP stock-based compensation expense will be recognized upfront, but cash outlay is deferred. The 10-year term is conventional. Investors should monitor cumulative grants to ensure dilution remains controlled, yet a single 21k-share award is unlikely to move the needle on intrinsic value.

Panoramica della segnalazione Form 4: Il 30/06/2025, MAIA Biotechnology, Inc. (simbolo MAIA) ha assegnato al direttore Cristian Luput un pacchetto di opzioni su azioni nell'ambito del Piano di Incentivazione Azionaria 2021 della società.

  • Opzioni assegnate: 21.350 opzioni per l'acquisto di azioni ordinarie.
  • Prezzo di esercizio: 1,80 $ per azione.
  • Piano di maturazione: 100% maturato immediatamente alla data di assegnazione.
  • Scadenza: 30/06/2035 (durata di 10 anni).
  • Detenzioni post-transazione: Luput detiene ora direttamente 21.350 strumenti derivati.

Non sono state segnalate transazioni su azioni non derivate e la comunicazione è stata effettuata individualmente dal direttore. L’assegnazione rappresenta una normale forma di compenso azionario finalizzata ad allineare gli interessi del direttore con il valore per gli azionisti, ma comporta un modesto aumento del numero totale di azioni diluite della società.

Resumen de la presentación del Formulario 4: El 30/06/2025, MAIA Biotechnology, Inc. (símbolo MAIA) otorgó al director Cristian Luput un paquete de opciones sobre acciones bajo el Plan de Incentivos de Capital 2021 de la empresa.

  • Opciones otorgadas: 21,350 opciones para comprar acciones ordinarias.
  • Precio de ejercicio: $1.80 por acción.
  • Calendario de adquisición: 100% adquirido inmediatamente en la fecha de otorgamiento.
  • Vencimiento: 30/06/2035 (plazo de 10 años).
  • Participaciones tras la transacción: Luput ahora posee directamente 21,350 valores derivados.

No se reportaron transacciones con acciones no derivadas y la presentación fue realizada individualmente por el director. La concesión representa una compensación accionaria rutinaria diseñada para alinear los incentivos del director con el valor para los accionistas, aunque aumenta modestamente el número total de acciones diluidas de la empresa.

Form 4 제출 개요: 2025� 6� 30�, MAIA Biotechnology, Inc. (티커 MAIA)� 이사 Cristian Luput에게 회사� 2021� 주식 인센티브 계획� 따라 주식 매수선택� 패키지� 부여했습니�.

  • 부여된 옵션: 보통� 21,350� 매수선택�.
  • 행사갶�: 주당 $1.80.
  • 권리 취득 일정: 부여일� 100% 즉시 취득.
  • 만료�: 2035� 6� 30� (10� 기간).
  • 거래 � 보유 현황: Luput� 현재 21,350개의 파생증권� 직접 보유 중입니다.

비파� 주식 거래� 보고되지 않았으며, 제출은 이사 개인� 직접 수행했습니다. 이번 부여는 이사� 인센티브� 주주 가치와 일치시키� 위한 일상적인 주식 보상으로, 회사� 완전 희석 주식 수를 다소 증가시키� 결과� 가져옵니다.

Résumé du dépôt du formulaire 4 : Le 30/06/2025, MAIA Biotechnology, Inc. (symbole MAIA) a accordé au directeur Cristian Luput un ensemble d’options d’achat d’actions dans le cadre du Plan d’Incitation en Actions 2021 de la société.

  • Options accordées : 21 350 options pour acheter des actions ordinaires.
  • Prix d’exercice : 1,80 $ par action.
  • Calendrier d’acquisition : 100 % acquis immédiatement à la date d’attribution.
  • Expiration : 30/06/2035 (durée de 10 ans).
  • Détentions après la transaction : Luput détient désormais directement 21 350 titres dérivés.

Aucune transaction sur actions non dérivées n’a été signalée, et le dépôt a été effectué individuellement par le directeur. Cette attribution représente une compensation en actions de routine visant à aligner les incitations du directeur avec la valeur pour les actionnaires, mais elle augmente modestement le nombre total d’actions diluées de la société.

Übersicht zur Form 4 Einreichung: Am 30.06.2025 gewährte MAIA Biotechnology, Inc. (Ticker MAIA) dem Direktor Cristian Luput ein Paket von Aktienoptionen im Rahmen des Aktienanreizplans 2021 des Unternehmens.

  • Gewährte Optionen: 21.350 Optionen zum Kauf von Stammaktien.
  • ܲüܲԲ𾱲: 1,80 $ pro Aktie.
  • Vesting-Zeitplan: 100 % sofort am Gewährungstag unverfallbar.
  • Ablaufdatum: 30.06.2035 (10 Jahre Laufzeit).
  • Bestände nach der Transaktion: Luput hält nun direkt 21.350 derivative Wertpapiere.

Es wurden keine Transaktionen mit nicht-derivativen Aktien gemeldet, und die Einreichung erfolgte individuell durch den Direktor. Die Gewährung stellt eine routinemäßige Aktienvergütung dar, die darauf abzielt, die Anreize des Direktors mit dem Aktionärswert in Einklang zu bringen, erhöht jedoch geringfügig die vollständig verwässerte Aktienanzahl des Unternehmens.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Lentz Daniel

(Last) (First) (Middle)
11305 FOUR POINTS DRIVE
BUILDING II, SUITE 100

(Street)
AUSTIN TX 78726

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
BigCommerce Holdings, Inc. [ BIGC ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
06/30/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Series 1 Common Stock 06/30/2025 F 3,339 D $5 256,501 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
Remarks:
/s/ Chuck Cassidy, Attorney-in-Fact for Lentz, Daniel 07/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many MAIA options did director Cristian Luput receive?

He received 21,350 stock options on 06/30/2025.

What is the exercise price of the new MAIA options?

The options carry an $1.80 per-share exercise price.

When do the options granted to Cristian Luput vest?

They vested 100% immediately on the grant date, 06/30/2025.

When do the MAIA Biotechnology director options expire?

The options expire on 06/30/2035, giving a 10-year exercise window.

Does this Form 4 indicate any sale or purchase of MAIA common shares?

No. The filing only reports a grant of derivative securities; no common shares were bought or sold.
Bigcommerce Holdings, Inc.

NASDAQ:BIGC

BIGC Rankings

BIGC Latest News

BIGC Latest SEC Filings

BIGC Stock Data

386.88M
66.91M
17.12%
73.47%
7.22%
Software - Application
Services-prepackaged Software
United States
AUSTIN